Free Trial
NASDAQ:TNDM

Tandem Diabetes Care Q2 2025 Earnings Report

Tandem Diabetes Care logo
$15.59 -0.58 (-3.59%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$15.74 +0.15 (+0.96%)
As of 07/11/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tandem Diabetes Care EPS Results

Actual EPS
N/A
Consensus EPS
-$0.40
Beat/Miss
N/A
One Year Ago EPS
N/A

Tandem Diabetes Care Revenue Results

Actual Revenue
N/A
Expected Revenue
$238.39 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tandem Diabetes Care Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Tandem Diabetes Care Earnings Headlines

Citigroup Reaffirms Sell Rating for Tandem Diabetes Care (NASDAQ:TNDM)
The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Something big is brewing in Washington. According to my research, an executive order from President Trump could be just weeks away. And it holds the potential to trigger one of the most explosive tech booms in US history. At the center of it all? Robots. Not the kind that clean your house or pour you coffee. But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year.
See More Tandem Diabetes Care Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tandem Diabetes Care? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tandem Diabetes Care and other key companies, straight to your email.

About Tandem Diabetes Care

Tandem Diabetes Care (NASDAQ:TNDM) (NASDAQ: TNDM) is a medical device company dedicated to improving the lives of people with diabetes through innovative insulin delivery systems and integrated software solutions. Founded in 2006 and headquartered in San Diego, California, Tandem designs, develops, and commercializes insulin pumps and technology platforms that enable better diabetes management. Since its initial public offering, the company has focused on combining sleek design, intuitive user interfaces, and advanced algorithms to streamline insulin therapy for patients worldwide.

The company’s flagship product, the t:slim X2® Insulin Pump, features a color touchscreen, rechargeable battery, and the ability to receive software updates without hardware replacement. Tandem has also introduced automated insulin delivery algorithms—Basal-IQ™ and Control-IQ™ technology—that integrate with continuous glucose monitoring (CGM) systems to predict and respond to glucose fluctuations. These systems offer features such as automated basal adjustments, correction boluses, and hypoglycemia prevention, empowering users with more precise control over their blood sugar levels.

Tandem Diabetes Care markets its products directly to patients, caregivers, and healthcare professionals through a dedicated sales force, distribution partners, and online channels. The company’s reach extends across the United States, Europe, Canada, Australia, and select markets in Asia and Latin America. By forging collaborative partnerships with payers, healthcare providers, and advocacy organizations, Tandem aims to expand access to its technology and support improved outcomes for people living with both type 1 and type 2 diabetes.

Led by founder and Chief Executive Officer John Sheridan, Tandem Diabetes Care maintains a strong focus on research and development, regulatory compliance, and customer service. The company’s leadership team includes seasoned professionals in engineering, operations, and finance who work together to drive innovation and operational excellence. As the diabetes technology market evolves, Tandem continues to invest in software enhancements, data analytics, and next-generation hardware to meet the needs of its growing customer base and uphold its mission of delivering life-changing solutions for diabetes management.

View Tandem Diabetes Care Profile

More Earnings Resources from MarketBeat